Westchester Neurovascular Symposium: Advances in Stroke Care. Westchester Medical Center, Valhalla, NY, November 15, 2019. Guest Editors: Justin Santarelli MD and Ramandeep Sahni MDDecision-Making for Patients With Cerebral Arteriovenous MalformationsAl-Mufti, Fawaz MD*,†; Stein, Alan MD†; Damodara, Nitesh MD†; Joseph-Senatus, Ganaelle BS†; Nuoman, Rolla MD‡; Nuoaman, Halla MD*; Ammar Adnan, Yasir MD*; Santarelli, Justin MD†; Sahni, Ramandeep MD*; Gandhi, Chirag D. MD†Author Information From the *Department of Neurology, Westchester Medical Center at New York Medical College, Valhalla, NY †Department of Neurosurgery, Westchester Medical Center at New York Medical College, Valhalla, NY ‡Department of Neurology, Maria Fareri Children’s Hospital - Westchester Medical Center at New York Medical College, Valhalla, NY. Disclosure: The authors have no conflicts of interest to report. Correspondence: Chirag D. Gandhi, MD, Department of Neurosurgery, Westchester Medical Center at New York Medical College, 100 Woods Road, Macy Pavilion 1331, Valhalla, NY 10595. E-mail: [email protected]. Cardiology in Review: January/February 2021 - Volume 29 - Issue 1 - p 10-14 doi: 10.1097/CRD.0000000000000342 Buy Metrics Abstract Cerebral arteriovenous malformations (AVMs) are a complex and heterogeneous pathology which require an understanding of the natural history of these lesions, as well as the potential treatment options in order to manage them safely. While treatment is the agreed upon strategy for most ruptured AVMs, the management of unruptured AVMs continues to be debated. More recently, this debate has been fueled by the A Randomized Trial of Unruptured Arteriovenous Malformations (ARUBA) trial which attempts to define the natural history and treatment risk of AVMs. However, the trial has significant shortcomings which limit its broad applicability. In addition, the breadth, efficacy, and safety of potential treatment options continue to improve. This review focuses on defining the natural history of cerebral AVMs, an overview of the ARUBA trial, and the most current treatment paradigm for cerebral AVMs. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.